Prospect for Immune Checkpoint Blockade: Dynamic and Comprehensive Monitorings Pave the Way

References

• Sharma P , AllisonJP . The future of immune checkpoint therapy . Science348 ( 6230 ), 56 – 61 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-CensitsJ , PowlesTet al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase II trial . Lancet387 ( 10031 ), 1909 – 1920 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Kaufman HL , RussellJ , HamidOet al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, Phase II trial . Lancet Oncol.17 ( 10 ), 1374 – 1385 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Massard C , GordonMS , SharmaSet al. Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer . J. Clin. Oncol.34 ( 26 ), 3119 – 3125 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ito A , KondoS , TadaK , KitanoS . Clinical development of immune checkpoint inhibitors . Biomed. Res. Int. 2015 , 605478 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Chapman PB , HauschildA , RobertCet al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation . N. Engl. J. Med.364 ( 26 ), 2507 – 2516 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kumarakulasinghe NB , Van ZanwijkN , SooRA . Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC) . Respirology20 ( 3 ), 370 – 378 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yu LY , TangJ , ZhangCMet al. New immunotherapy strategies in breast cancer . Int. J. Environ. Res. Public Health14 ( 1 ), doi:10.3390/ijerph14010068 ( 2017 ).
   Web of Science ®Google Scholar
• Dunn GP , OldLJ , SchreiberRD . The immunobiology of cancer immunosurveillance and immunoediting . Immunity21 ( 2 ), 137 – 148 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Boussiotis VA . Molecular and biochemical aspects of the PD-1 checkpoint pathway . N. Engl. J. Med.375 ( 18 ), 1767 – 1778 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Joyce JA , FearonDT . T cell exclusion, immune privilege, and the tumor microenvironment . Science348 ( 6230 ), 74 – 80 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS , BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer . N. Engl. J. Med.366 ( 26 ), 2443 – 2454 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Taube JM , KleinA , BrahmerJRet al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy . Clin. Cancer. Res.20 ( 19 ), 5064 – 5074 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Chen N , FangW , ZhanJet al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation . J. Thorac. Oncol.10 ( 6 ), 910 – 923 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Casey SC , TongL , LiYet al. MYC regulates the antitumor immune response through CD47 and PD-L1 . Science352 ( 6282 ), 227 – 231 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Kaufman HL . Precision immunology: the promise of immunotherapy for the treatment of cancer . J. Clin. Oncol.33 ( 12 ), 1315 – 1317 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Alexandrov LB , Nik-ZainalS , WedgeDCet al. Signatures of mutational processes in human cancer . Nature500 ( 7463 ), 415 – 421 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rizvi NA , HellmannMD , SnyderAet al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer . Science348 ( 6230 ), 124 – 128 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Van Allen EM , MiaoD , SchillingBet al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma . Science350 ( 6257 ), 207 – 211 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Scarpa M , RuffoloC , CanalFet al. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance . Oncotarget6 ( 41 ), 43472 – 43482 ( 2015 ).
   PubMedGoogle Scholar
• Le DT , UramJN , WangHet al. PD-1 blockade in tumors with mismatch-repair deficiency . N. Engl. J. Med.372 ( 26 ), 2509 – 2520 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kawakami H , ZaananA , SinicropeFA . Microsatellite instability testing and its role in the management of colorectal cancer . Curr. Treat. Options Oncol.16 ( 7 ), 30 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zaragoza J , CailleA , BenetonNet al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma . Br. J. Dermatol.174 ( 1 ), 146 – 151 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ferrucci PF , GandiniS , BattagliaAet al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients . Br. J. Cancer112 ( 12 ), 1904 – 1910 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Delyon J , MateusC , LefeuvreDet al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival . Ann. Oncol.24 ( 6 ), 1697 – 1703 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gebhardt C , SevkoA , JiangHet al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab . Clin. Cancer. Res.21 ( 24 ), 5453 – 5459 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Feng Z , PuriS , MoudgilTet al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma . J. Immunother. Cancer3 , 47 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wang W , YuD , SarnaikAAet al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment . J. Transl. Med.10 , 146 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Khan MA , ChenHC , WanXXet al. Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells . Mol. Cells35 ( 3 ), 219 – 225 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kelderman S , HeemskerkB , Van TinterenHet al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma . Cancer Immunol. Immunother.63 ( 5 ), 449 – 458 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Calcinotto A , FilipazziP , GrioniMet al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes . Cancer Res.72 ( 11 ), 2746 – 2756 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fischer K , HoffmannP , VoelklSet al. Inhibitory effect of tumor cell-derived lactic acid on human T cells . Blood109 ( 9 ), 3812 – 3819 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Coussens LM , ZitvogelL , PaluckaAK . Neutralizing tumor-promoting chronic inflammation: a magic bullet?Science339 ( 6117 ), 286 – 291 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Coffelt SB , KerstenK , DoornebalCWet al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis . Nature522 ( 7556 ), 345 – 348 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zelenay S , Van Der VeenAG , BottcherJPet al. Cyclooxygenase-dependent tumor growth through evasion of immunity . Cell162 ( 6 ), 1257 – 1270 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gajewski TF , LouahedJ , BrichardVG . Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy . Cancer J.16 ( 4 ), 399 – 403 ( 2010 ).
   PubMed Web of Science ®Google Scholar